

Decision Point: GF/B40/EDP10: Decision on the Secretariat's Recommendation on Additional Funding to Finance Unfunded Quality Demand from the 2017-2019 Allocation Period

The Board:

1. Approves the revised budget recommended for each grant listed in Table 2 of GF/B40/ER10 ("Table 2");
2. Affirms the additional funding approved under this decision (a) increases the upper-ceiling amount that may be available for the relevant implementation period of each country disease component's constituent grants, and (b) is subject to the availability of funding; and
3. Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the "TRP") validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.

Table 2: Secretariat's Recommendation on integration of Additional Funding to Finance UQD from the 2017-2019 Allocation Period - Please note that each country name is linked to the extranet site where supporting documents are available for review

N	Applicant	Disease Component	Grant Name	Additional Funding Source	Currency	Previously Approved Program Budget	Recommended Additional Funding	Revised Program Budget
1	Armenia	TB/HIV	ARM-C-MOH	Portfolio optimization	USD	N/A	300,000	7,923,240
2	Malawi	TB/HIV	MWI-C-MOH	Portfolio optimization	USD	364,669,494	5,000,000	369,669,494
3	Niger	Malaria	NER-M-CRS	Portfolio optimization	EUR	49,023,326	11,831,103	60,854,429
4	Philippines	TB	PHL-T-PBSP	Portfolio optimization	USD	98,543,887	10,000,000	108,543,887
5	Togo	Malaria	TGO-M-PMT	Portfolio optimization	EUR	30,243,585	1,336,650	31,580,235